The Pharmaceutical Application Term Sheet Provides Enveric Biosciences Could Be Eligible To Receive Future Development And Sales Milestone Payments That In Total Could Add Up To Approximately $61M
Portfolio Pulse from Benzinga Newsdesk
Enveric Biosciences could receive up to $61M in future development and sales milestone payments, with royalty rates ranging from 2.5% to 10% on future sales based on sales criteria.
March 19, 2024 | 11:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Enveric Biosciences could receive up to $61M in future milestone payments and royalties between 2.5% to 10% on future sales.
The potential to receive up to $61M in milestone payments and royalties ranging from 2.5% to 10% on future sales indicates a significant financial opportunity for Enveric Biosciences. This could lead to increased investor confidence and a positive impact on the stock price in the short term, assuming the market perceives this news as a strong indicator of future revenue growth.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100